A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.
一种新型PLpro抑制剂改善了新冠肺炎长期症状的临床前模型的结果
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-57905-4
M Bader Stefanie, Calleja Dale J, Devine Shane M, Kuchel Nathan W, Lu Bernadine G C, Wu Xinyu, Birkinshaw Richard W, Bhandari Reet, Loi Katie, Volpe Rohan, Khakham Yelena, Au Amanda E, Blackmore Timothy R, Mackiewicz Liana, Dayton Merle, Schaefer Jan, Scherer Lena, Stock Angus T, Cooney James P, Schoffer Kael, Maluenda Ana, Kleeman Elizabeth A, Davidson Kathryn C, Allison Cody C, Ebert Gregor, Chen Gong, Katneni Kasiram, Klemm Theresa A, Nachbur Ueli, Georgy Smitha Rose, Czabotar Peter E, Hannan Anthony J, Putoczki Tracy L, Tanzer Maria, Pellegrini Marc, Lechtenberg Bernhard C, Charman Susan A, Call Melissa J, Mitchell Jeffrey P, Lowes Kym N, Lessene Guillaume, Doerflinger Marcel, Komander David
